08:10 AM EDT, 04/19/2024 (MT Newswires) -- Spyre Therapeutics ( SYRE ) filed a mixed-securities shelf registration Thursday with the US Securities and Exchange Commission for the potential resale of around 33.4 million of its common shares by selling shareholders.

The company said the selling shareholders were offering to resell up to 22,496,402 shares of Common Stock, along with 10,865,000 shares of Common Stock issuable upon the conversion of 271,625 shares of Series B Preferred Stock, for a total of 33,361,402 shares.

The company said it would not receive proceeds from the resale of the shares by the selling shareholders.